Results 81 to 90 of about 311 (111)

Advisory Council on the Misuse of Drugs’ (ACMD) advice on: i) somapacitan, lonapegsomatropin, and somatrogon, ii) zuranolone, and iii) ganaxolone.

core  

Somatrogon: First Approval

Drugs, 2022
Somatrogon (NGENLA®), a long-acting human growth hormone based on C-terminal peptide technology, is in development by Pfizer and OPKO Health for the treatment of growth hormone deficiency in pediatric and adult patients. Administered as a once-weekly subcutaneous injection, somatrogon reduces treatment burden relative to once-daily human growth hormone
Yvette N Lamb
exaly   +5 more sources

Somatrogon

Reactions Weekly, 2018
core   +10 more sources

Somatrogon (Ngenla)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Ngenla should be reimbursed by public drug plans for the treatment of growth hormone deficiency if certain conditions are met. Ngenla should only be covered to treat children who are at least 3 years of age, who did not reach puberty yet, and who are diagnosed with growth hormone deficiency. Ngenla should only ...
null CADTH
core   +4 more sources

Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. [PDF]

Journal of Clinical Endocrinology and Metabolism, 2022
Context: Somatrogon is a long-acting recombinant human growth hormone (rhGH) in development for once-weekly treatment of children with growth hormone deficiency (GHD). Objective: We aimed to compare the efficacy and safety of once-weekly somatrogon with
Moshe Phillip, Ho-Seong Kim, Bradley Miller   +2 more
exaly   +2 more sources

An Open-Label Extension of a Phase 2 Dose-Finding Study of Once-Weekly Somatrogon vs. Once-Daily Genotropin in Children With Short Stature Due to Growth Hormone Deficiency: Results Following 5 Years of Treatment

Journal of Pediatric Endocrinology and Metabolism, 2023
Nataliya Zelinska, Nelly Mauras, Violeta Iotova   +2 more
exaly   +2 more sources

Efficacy and Safety of Once-Weekly Somatrogon Compared With Once-Daily Somatropin (Genotropin®) in Japanese Children With Pediatric Growth Hormone Deficiency: Results From a Randomized Phase 3 Study

Hormone Research in Paediatrics, 2022
Roy Gomez, Tohru Yorifuji, Aleksandra Pastrak   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Somatrogon in Paediatric Growth Hormone Deficiency: A Profile of Its Use in the EU

Drugs and Therapy Perspectives, 2022
Zaina T Al-Salama, Esther S Kim
exaly   +2 more sources